In CONCUR, higher than grade III Regorafenib-related AEs were hand-foot skin reaction (16%), hypertension (11%), hyperbilirubinaemi (7%), hypophosphataemia (7%), ALT increased (7%), AST increased (6%), lipase increased (4%), and maculopapular rash (4%). The gene discussed is GPT; the disease is hypertensive disorder.